Cargando…

Tamoxifen induces radioresistance through NRF2-mediated metabolic reprogramming in breast cancer

BACKGROUND: Recently, we reported that tamoxifen-resistant (TAM-R) breast cancer cells are cross-resistant to irradiation. Here, we investigated the mechanisms associated with tamoxifen-induced radioresistance, aiming to prevent or reverse resistance and improve breast cancer treatment. METHODS: Wil...

Descripción completa

Detalles Bibliográficos
Autores principales:	Naumann, F. V., Sweep, F. C. G. J., Adema, G. J., Peeters, W. J. M., Martens, J. W. M., Bussink, J., Span, P. N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909892/ https://www.ncbi.nlm.nih.gov/pubmed/36755288 http://dx.doi.org/10.1186/s40170-023-00304-4

Ejemplares similares

Changes in DNA Damage Repair Gene Expression and Cell Cycle Gene Expression Do Not Explain Radioresistance in Tamoxifen-Resistant Breast Cancer
por: Post, Annemarie E. M., et al.
Publicado: (2020)

The Role of Hypoxia and the Immune System in Tumor Radioresistance
por: Span, Paul N., et al.
Publicado: (2019)

Carbonic anhydrase IX expression is more predictive than prognostic in breast cancer
por: Span, P N, et al.
Publicado: (2007)

Carbonic anhydrase-9 expression levels and prognosis in human breast cancer: association with treatment outcome
por: Span, P N, et al.
Publicado: (2003)

Regulation of TRIB3 mRNA and Protein in Breast Cancer
por: Wennemers, Marloes, et al.
Publicado: (2012)

4‐protein signature predicting tamoxifen treatment outcome in recurrent breast cancer
por: De Marchi, Tommaso, et al.
Publicado: (2015)

The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer
por: Law, Emily K., et al.
Publicado: (2016)

Annexin-A1 and caldesmon are associated with resistance to tamoxifen in estrogen receptor positive recurrent breast cancer
por: De Marchi, Tommaso, et al.
Publicado: (2015)

Hypoxia stimulates migration of breast cancer cells via the PERK/ATF4/LAMP3-arm of the unfolded protein response
por: Nagelkerke, Anika, et al.
Publicado: (2013)

Phosphoserine aminotransferase 1 is associated to poor outcome on tamoxifen therapy in recurrent breast cancer
por: De Marchi, Tommaso, et al.
Publicado: (2017)

Association of tamoxifen resistance and lipid reprogramming in breast cancer
por: Hultsch, Susanne, et al.
Publicado: (2018)

Quantitative Imaging of Hypoxic CAIX-Positive Tumor Areas with Low Immune Cell Infiltration in Syngeneic Mouse Tumor Models
por: Boreel, Daan F., et al.
Publicado: (2023)

Inside the hypoxic tumour: reprogramming of the DDR and radioresistance
por: Begg, Katheryn, et al.
Publicado: (2020)

Tamoxifen metabolism: pharmacokinetic and in vitro study.
por: Etienne, M. C., et al.
Publicado: (1989)

Nrf2-Mediated Metabolic Reprogramming in Cancer
por: Wang, Yan-Yang, et al.
Publicado: (2018)

ACLY (ATP Citrate Lyase) Mediates Radioresistance in Head and Neck Squamous Cell Carcinomas and is a Novel Predictive Radiotherapy Biomarker
por: Göttgens, Eva-Leonne, et al.
Publicado: (2019)

Influence of the antioestrogen tamoxifen on normal breast tissue.
por: Walker, K. J., et al.
Publicado: (1991)

Imaging carbonic anhydrase IX as a method for monitoring hypoxia-related radioresistance in preclinical head and neck cancer models
por: Huizing, Fokko J., et al.
Publicado: (2021)

The mechanism of tamoxifen in breast cancer prevention
por: Yu, F, et al.
Publicado: (2001)

Ovarian cysts in women receiving tamoxifen for breast cancer
por: Mourits, M J E, et al.
Publicado: (1999)

Expression of carbonic anhydrase IX suggests poor response to therapy in rectal cancer
por: Span, P N, et al.
Publicado: (2009)

Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side study
por: van Nes, J. G. H., et al.
Publicado: (2012)

NRF2-pathway mutations predict radioresistance in non-small cell lung cancer
por: Kinslow, Connor J., et al.
Publicado: (2022)

Phosphorylation independent eIF4E translational reprogramming of selective mRNAs determines tamoxifen resistance in breast cancer
por: Gong, Chun, et al.
Publicado: (2020)

Nrf2 activation reprograms macrophage intermediary metabolism and suppresses the type I interferon response
por: Ryan, Dylan G., et al.
Publicado: (2022)

Letter to the editor: Hypoxia kinetics and histology in combined radiotherapy and oxidative phosphorylation inhibition effects on antitumor immunity
por: Boreel, Daan F, et al.
Publicado: (2021)

Keap1-Nrf2 Pathway Regulates ALDH and Contributes to Radioresistance in Breast Cancer Stem Cells
por: Kamble, Dinisha, et al.
Publicado: (2021)

NRF2 Orchestrates the Metabolic Shift during Induced Pluripotent Stem Cell Reprogramming
por: Hawkins, Kate E., et al.
Publicado: (2016)

Cell-free DNA mutations as biomarkers in breast cancer patients receiving tamoxifen
por: Jansen, Maurice P.H.M., et al.
Publicado: (2016)

Metabolic reprogramming during neuronal differentiation
por: Agostini, M, et al.
Publicado: (2016)

Tribbles homolog 3 denotes a poor prognosis in breast cancer and is involved in hypoxia response
por: Wennemers, Marloes, et al.
Publicado: (2011)

Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer.
por: Foekens, J. A., et al.
Publicado: (1994)

The antioxidative stress regulator Nrf2 potentiates radioresistance of oral squamous cell carcinoma accompanied with metabolic modulation
por: Matsuoka, Yuichiro, et al.
Publicado: (2022)

Breast cancer chemoprevention: beyond tamoxifen
por: Fabian, Carol J
Publicado: (2001)

Concentrations of tamoxifen and its major metabolites in hormone responsive and resistant breast tumours
por: MacCallum, J, et al.
Publicado: (2000)

Tamoxifen, serum lipoproteins and cardiovascular risk.
por: Bruning, P. F., et al.
Publicado: (1988)

Transcriptional and metabolic reprogramming induce an inflammatory phenotype in non-medullary thyroid carcinoma-induced macrophages
por: Arts, Rob J. W., et al.
Publicado: (2016)

High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer
por: Jansen, M. P. H. M., et al.
Publicado: (2011)

Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer
por: Saladores, P, et al.
Publicado: (2015)

Association of microRNA-7 and its binding partner CDR1-AS with the prognosis and prediction of 1(st)-line tamoxifen therapy in breast cancer
por: Uhr, K., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_fed79roimd50eqisgm7spampnv